Search
Zimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving … Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeVoxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigationalthe data [A235720] and aducanumab was granted accelerated FDA approval on 7 June 2021. … [A235668] Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking aducanumab showed signs of slowing progression; however, these data were controversial.
Bimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigationalBimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. … [L6877,L6892,L6898,L12069] Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.
Synonyms: (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamideMixtures: BİMAPRESS DUO 0,3 MG/ML+5 MG/ML GÖZ DAMLASI, ÇÖZELTİ, 1 ADET, GANFORT® UD SOLUCION OFTALMICAPromethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigationalPromethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. … [A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.
Synonyms: N,N,α-trimethyl-10H-phenothiazine-10-ethanamine, N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamineMixtures: Promethazine DM, Promethazine DMAloe vera leaf
go.drugbank.com/drugs/DB13906ApprovedInvestigationalThe active constituents of aloe vera include polysaccharides with protective effects on skin, as they exhibit antioxidant and anti-inflammatory properties [A32481]. … Aloe vera, or _Aloe barbadensis miller_, is the most common species of Aloe that is cultivated for agricultural and medical purposes.
Mixtures: One Time Compound Benzoin Tct F466Synonyms: Lu hui ye, Lu hui (aloe vera)mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.
Romosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalRomosozumab was granted FDA approval on April 9,2019[L5921]. … Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant
Categories: Drugs for Treatment of Bone DiseasesProducts: EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML, EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105MG/1.17MLTrovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. … Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Daratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigational[A199002] Daratumumab was granted FDA approval on 16 November 2015. … This approval was based on results from the Phase 3 PERSEUS study, which demonstrated significant improvement in progression-free survival and higher rates of minimal residual disease (MRD) negativity
Categories: CD38 (Clusters of Differentiation 38) inhibitors